December 6, 2022

Sell Shockwave Medical (SWAV)

Today SWAV has dipped below support near 235, triggering my mental stop-loss level. We’ve previously locked in a profit of 30% on the first half of this position. Today, we’ll sell the second half to lock in a return that should be around 45%. Please note that I still like SWAV; however, the market is looking suspect once again and a “strong” stock moving below support isn’t one I want to be overly patient with. I will keep an eye on SWAV and consider adding it back in the future. SELL

Tyler Laundon

Tyler Laundon is chief analyst of the limited-subscription advisory, Cabot Small-Cap Confidential and grand slam advisory Cabot Early Opportunities. He has spent his entire career managing, consulting and analyzing start-up and small-cap companies. His hands-on experience has taught Tyler that the development of a superior business model is the biggest factor in determining a company’s long-term success. Accordingly, his research focuses on assessing the viability of management’s growth strategies, trends in addressable markets and achievement of major developmental milestones.